Capivasertib and ipatasertib [12] (both AKT inhibitors) have both demonstrated clinical activity in combination with paclitaxel in triple-negative-breast cancer (TNBC) in Phase II clinical studies [13, 14], with more pronounced benefit in patients with PIK3CA/AKT1/PTEN mutant tumours. Here, AKT1 is linked to neoplasm.